Oncoimmune, Inc. clinical trials
Acquired by Merck & Co., Inc, Dec 2020 · source ↗
The registry lists 6 studies whose lead sponsor is Oncoimmune, Inc. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jan 23, 2024.
- 6studies on the registry
- 0open to participants now
Before and after it joined Merck & Co., Inc
- First submitted before Oncoimmune, Inc. became part of Merck & Co., Inc
- 6
- First submitted after Oncoimmune, Inc. became part of Merck & Co., Inc
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
What it is testing
The drugs Oncoimmune, Inc.’s studies test, most studies first; none is open now — 1 drug with a page of their own. Each count opens the studies in search.
Studies, none open
- efprezimod alfa2 in phase 30 open · 6
All 6 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
Over the years
- 14
- 15
- 16
- 17
- 18
- 19
- 220
- 21
- 22
- 23
- 24
- 25
- 026
By the year each study started. 2026 so far in the lighter column.
Registry sponsor names on this page
- Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)6 studies
Something wrong with this grouping? Tell us on the Merck & Co., Inc page.
Studies
Recruiting first, then most recently updated. Showing 6 of 6. All Merck & Co., Inc studies →
- Phase II Trial of Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft-Versus-Host Disease (GVHD) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-002)CompletedNCT02663622Phase 2
Sponsor listed in the registry: Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Oncoimmune, Inc. became part of Merck & Co., Inc
- Efprezimod Alfa (CD24Fc, MK-7110) as a Non-antiviral Immunomodulator in COVID-19 Treatment (MK-7110-007)CompletedNCT04317040Phase 3
Sponsor listed in the registry: Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Oncoimmune, Inc. became part of Merck & Co., Inc
- Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005)TerminatedNCT04095858Phase 3
Sponsor listed in the registry: Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Oncoimmune, Inc. became part of Merck & Co., Inc
- Efprezimod Alfa (CD24Fc, MK-7110) Administration to Decrease Low-Density Lipoprotein (LDL) and Inflammation in Human Immunodeficiency Virus (HIV) Patients (CALIBER) (MK-7110-003)TerminatedNCT03960541Phase 2
Sponsor listed in the registry: Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Oncoimmune, Inc. became part of Merck & Co., Inc
- Safety Study of Efprezimod Alfa (CD24Fc, MK-7110) When Administered Intravenously in Healthy Adult Subjects (MK-7110-001)CompletedNCT02650895Phase 1
Sponsor listed in the registry: Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Oncoimmune, Inc. became part of Merck & Co., Inc
- CD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI)WithdrawnNCT04060407Phase 1/2
Sponsor listed in the registry: Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before Oncoimmune, Inc. became part of Merck & Co., Inc